← Back to all trials
Recruiting
NCT05637086
Clinical Study Evaluating Safety of Pentoxifylline in Patients With Grand-Mal Epilepsy Treated by Phenytoin Monotherapy
Conditions: Epilepsy
Sex: All
Ages: 18 Years – 75 Years
Phase: PHASE2
Enrollment: 60
Sponsor: Mostafa Bahaa
Location: Egypt
Summary
Epilepsy is a chronic neurological disorder affecting millions of people all over the world.
Epileptic seizures are caused by abnormal synchronized electrical neuronal discharges that could be either focal or widespread.
Pathogenesis of epilepsy involves multiple processes including genetics, oxidative stress, ion channels, neuroinflammation, and cellular damage through autophagy and apoptosis.Neuroinflammation is considered one of the most important factors contributing critically to epileptogenesis.
Eligibility Criteria
Inclusion Criteria:- Patients aged ≥ 18 years old.
Patients with grand mal epilepsy on phenytoin monotherapy.
Women with a negative pregnancy test and women on effective contraceptionExclusion Criteria:- Patients with significant liver and kidney function abnormalities.
Alcohol and/or drug abusers.
Patients with known allergies to the study medications Patients with known allergy to sulfonamides (cross hypersensitivity with celecoxib).Pregnant women and women with a planned pregnancy.
Subjects on medication are known to have possible positive effects on epilepsy.
Patients who are currently using other antiepileptic drugs.
Patients with CVD and a history of coronary artery bypass graft (CABG) surgery.
Patients on aspirin or fluconazole therapy Patients with a recent retinal or cerebral hemorrhage
Source: ClinicalTrials.gov (NCT05637086). StuddyBuddy aggregates publicly available trial information.